---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-201709"
form_type: "8-K"
ticker: "STAA"
cik: "0000718937"
company_name: "STAAR SURGICAL CO"
filed_at: "2023-08-02T23:59:59+00:00"
generated_at: "2026-06-12T15:28:25.844366+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# STAAR Surgical Q2 ICL sales record $93.1M; GAAP EPS $0.12; guides FY ICL sales $320M-$325M

## Summary
- Record ICL sales of $93.1M, +19% YoY; ICL units +21% YoY.
- Net sales $92.3M (+14% YoY); GAAP EPS $0.12 vs $0.26 prior year; adjusted ICL EPS $0.19.
- Updated FY2023 ICL sales outlook to $320M-$325M (midpoint ~20% growth).
- APAC ICL sales grew 26% YoY; U.S. ICL sales +10% vs industry -15%.
- Gross margin 76.6% vs 78.8% prior year; cash & investments $209.5M.

## SEC filing metadata
- accession: 0001193125-23-201709
- form_type: 8-K
- ticker: STAA
- cik: 0000718937
- company_name: STAAR SURGICAL CO
- filed_at: 2023-08-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/718937/000119312523201709/0001193125-23-201709-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/718937/000119312523201709/d495417d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-201709
- JSON: https://secwatch.observer/filing/0001193125-23-201709.json
- Plain text: https://secwatch.observer/filing/0001193125-23-201709.txt

## Key facts
- Earnings Releases
  STAAR SURGICAL CO reported the second quarter ended June 30, 2023 results: revenue $92.3 million, net income $6.1 million or $0.12 per diluted share, EPS $0.12 per diluted share. Guidance lowered.
  - Period: the second quarter ended June 30, 2023
  - Revenue: $92.3 million
  - Net income: $6.1 million or $0.12 per diluted share
  - EPS: $0.12 per diluted share
  - Guidance: lowered
  - Result: reported results
  source text: and marketer of implantable lenses for the eye, today reported financial results for the second quarter ended June 30, 2023. Second Quarter 2023 Overview • Net Sales of $92.3 Million Up 14% includes a $0.7 Million sales reduction related to Other Products • Record ICL Sales of $93.1 Million Up 19% Y/Y and Up 20% Y/Y in Constant Currency • ICL Units Up 21% Y/Y
  evidence_url: https://www.sec.gov/Archives/edgar/data/718937/000119312523201709/0001193125-23-201709-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.